About The Event

ISPOR is fast approaching and we couldn't be more excited to exhibit our solutions.  If you are planning on attending, please stop by our booth #812.

May 20-24, 2017
Hynes Convention Center
Boston, MA
Booth #812
Panel Discussions

Monday, May 22 | 6:15 pm

New Trends of Health Technology Assessment Development and Value Evidence Requirement for Access and Reimbursement in Asia (China, Japan, South Korea, and Taiwan)

Bruce Crawford, MA, MPH

Vice President,
Real-World Evidence & Insights,

Tuesday, May 23 | 2:15 pm

Will the 21st Century Cures Act Drive Conduct of Pragmatic Clinical Trials?

David Thompson, PhD
Senior Vice President,
Real-World Evidence & Insights,
inVentiv Health
Educational Symposium

Wednesday, May 24 | 12:30 pm

Evidentiary Equilibrium: Balancing Real-World Evidence Development with Stakeholder Requirements

David Thompson, PhD

Senior Vice President,
Real-World Evidence & Insights,
inVentiv Health
Newell McElwee, PharmD, MSPH

Vice President,
Health Economics and Outcomes Research,

Jay McKnight, PharmD, BCPS

Pharmacy Clinical Strategies,
Eleanor M. Perfetto, PhD, MS

Senior Vice President, Strategic Initiatives, National Health Council Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy


Wednesday, May 24 | 1:45 pm

Biosimilars in the US - An Opportunity Lost or in the Making

Discussion Leader:
Monique Martin,
PharmD, MSc, MBA
Managing Director,
PMA Europe
Discussion Leader:
Keith Kelly, BBA
Practice Area Lead,

Wednesday, May 24 | 1:45 pm

Quantifying Efficiency in Health Care: Time and Motion Methodology to Generate Robust Economic Evidence for Drugs and Medical Devices

Discussion Leader:
Erwin De Cock, MSc
Real-World Evidence & Insights
Discussion Leader:
Florian Eichmann, PhD
Real-World Evidence & Insights
inVentiv Health by the Numbers
> 15,000 inVentiv Health Experts
helping global clients realize their goals in clinical development and commercialization.
> 90 Countries  
in which inVentiv Health has the ability to support clients.
550 Global Pharmaceutical Companies
have turned to inVentiv Health for expertise, skills and insight.
inVentiv Health is one of the nation's largest providers of direct-to-patient communcations with real-time access to 9 years of data that includes:
30,000 Pharmacies
194M+ Health Consumers
285,000 Physicians
2.2 Billion Annual Prescriptions
60% of all retail prescriptions
across 35 chains
In the past 5 years, inVentiv Health has helped to develop or commercialize:
Approved by the FDA
Novel New Drugs
Novel New Oncology Drugs
Novel New Central Nervous System Drugs
Approved by the EMA
Products Granted Marketing Authorization
Oncology Drugs
Central Nervous System Drugs